November 10, 2020

Skin cancer drug not cost effective

NICE has today (Thursday 5 November 2020) started a consultation on draft guidance which does not recommend the routine use of nivolumab (Opdivo; Bristol-Myers Squibb) as an option after surgery for some people with melanoma.

Following a review, an independent NICE technology appraisal committee said the most likely cost-effective estimates on the use of nivolumab are above what NICE considers a good use of NHS resources.  

Read more – NICE (5/11/20)

Leave a Reply

Your email address will not be published. Required fields are marked *